Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Fasenra Generic Name & Formulations
Legal Class
Rx
General Description
Benralizumab 30mg/mL; soln for SC inj; preservative-free.
Pharmacological Class
Interleukin-5 antagonist.
How Supplied
Single-dose prefilled syringe—1; Single-dose autoinjector (pen)—1
Manufacturer
Generic Availability
NO
Fasenra Indications
Indications
As add-on maintenance treatment of severe asthma in patients ≥12yrs old, and with an eosinophilic phenotype.
Limitations of Use
Not for treating other eosinophilic conditions. Not for relief of acute bronchospasm or status asthmaticus.
Fasenra Dosage and Administration
Adult
Give by SC inj into upper arm, thigh, or abdomen. 30mg once every 4 weeks for the first 3 doses, then once every 8 weeks thereafter.
Children
<12yrs: not established.
Fasenra Contraindications
Not Applicable
Fasenra Boxed Warnings
Not Applicable
Fasenra Warnings/Precautions
Warnings/Precautions
Not for treating acute asthma symptoms or exacerbations. Discontinue if hypersensitivity reactions occur. Treat pre-existing helminth infections before initiating therapy; discontinue Fasenra if treatment-resistant infection occurs while on therapy until resolves. Avoid abrupt discontinuation of systemic or inhaled corticosteroids; reduce dose gradually upon Fasenra initiation, if appropriate. Reduction may be associated with systemic withdrawal symptoms and/or unmask previously suppressed conditions. Pregnancy. Nursing mothers.
Fasenra Pharmacokinetics
See Literature
Fasenra Interactions
Fasenra Adverse Reactions
Adverse Reactions
Headache, pharyngitis, pyrexia, hypersensitivity reactions.
Fasenra Clinical Trials
See Literature
Fasenra Note
Not Applicable
Fasenra Patient Counseling
See Literature
Images
